The immunological network: Novel approaches to the treatment of Crohn's disease

Research output: Contribution to journal › Review › Research › peer-review

Standard

The immunological network : Novel approaches to the treatment of Crohn's disease. / Davidsen, B.; Nielsen, O. H.; Vainer, B.; Kirman, I.

In: Expert Opinion on Investigational Drugs, Vol. 5, No. 5, 01.01.1996, p. 555-564.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Davidsen, B, Nielsen, OH, Vainer, B & Kirman, I 1996, 'The immunological network: Novel approaches to the treatment of Crohn's disease', Expert Opinion on Investigational Drugs, vol. 5, no. 5, pp. 555-564.

APA

Davidsen, B., Nielsen, O. H., Vainer, B., & Kirman, I. (1996). The immunological network: Novel approaches to the treatment of Crohn's disease. Expert Opinion on Investigational Drugs, 5(5), 555-564.

Vancouver

Davidsen B, Nielsen OH, Vainer B, Kirman I. The immunological network: Novel approaches to the treatment of Crohn's disease. Expert Opinion on Investigational Drugs. 1996 Jan 1;5(5):555-564.

Author

Davidsen, B. ; Nielsen, O. H. ; Vainer, B. ; Kirman, I. / The immunological network : Novel approaches to the treatment of Crohn's disease. In: Expert Opinion on Investigational Drugs. 1996 ; Vol. 5, No. 5. pp. 555-564.

Bibtex

@article{991a985080ce45ba8006fd96e45d1d8b,
title = "The immunological network: Novel approaches to the treatment of Crohn's disease",
abstract = "This article reviews experimental laboratory and preliminary clinical studies, which might lead to novel approaches in the treatment of Crohn's disease (CD). Some of the new agents might be of value for subgroups of CD patients, especially those who have been drug resistant to the 'classical therapy' with agents like glucocorticoids, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. However, controlled trials for the novel agents mentioned in this review are highly warranted.",
keywords = "Antibodies, Crohn's disease, Cytokines, Disease modulation, Immunology, Immunomodulation, Inflammation, Intestinal mucosa, Pharmacotherapeutics",
author = "B. Davidsen and Nielsen, {O. H.} and B. Vainer and I. Kirman",
year = "1996",
month = jan,
day = "1",
language = "English",
volume = "5",
pages = "555--564",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "5",

}

RIS

TY - JOUR

T1 - The immunological network

T2 - Novel approaches to the treatment of Crohn's disease

AU - Davidsen, B.

AU - Nielsen, O. H.

AU - Vainer, B.

AU - Kirman, I.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - This article reviews experimental laboratory and preliminary clinical studies, which might lead to novel approaches in the treatment of Crohn's disease (CD). Some of the new agents might be of value for subgroups of CD patients, especially those who have been drug resistant to the 'classical therapy' with agents like glucocorticoids, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. However, controlled trials for the novel agents mentioned in this review are highly warranted.

AB - This article reviews experimental laboratory and preliminary clinical studies, which might lead to novel approaches in the treatment of Crohn's disease (CD). Some of the new agents might be of value for subgroups of CD patients, especially those who have been drug resistant to the 'classical therapy' with agents like glucocorticoids, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. However, controlled trials for the novel agents mentioned in this review are highly warranted.

KW - Antibodies

KW - Crohn's disease

KW - Cytokines

KW - Disease modulation

KW - Immunology

KW - Immunomodulation

KW - Inflammation

KW - Intestinal mucosa

KW - Pharmacotherapeutics

UR - http://www.scopus.com/inward/record.url?scp=0029994839&partnerID=8YFLogxK

M3 - Review

AN - SCOPUS:0029994839

VL - 5

SP - 555

EP - 564

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -

ID: 218718880